Get the Stockscreener App
2.405
3.02%
-0.075
Lisata Therapeutics Inc stock is traded at $2.405, with a volume of 30,489.
It is down -3.02% in the last 24 hours and down -10.26% over the past month.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
See More
Previous Close:
$2.48
Open:
$2.48
24h Volume:
30,489
Relative Volume:
0.75
Market Cap:
$20.19M
Revenue:
-
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.9582
EPS:
-2.51
Net Cash Flow:
$-18.90M
1W Performance:
-3.80%
1M Performance:
-10.26%
6M Performance:
-19.83%
1Y Performance:
-19.57%
1-Day Range:
$2.35
$2.48
1-Week Range:
$2.35
$2.71
52-Week Range:
$2.19
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.405 | 20.19M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Lisata Therapeutics Inc expected to post a loss of 76 cents a shareEarnings Preview - TradingView
LSTALisata Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Lisata Therapeutics to Report Full Year 2024 Financial - GlobeNewswire
Lisata Therapeutics Earnings Call: 2024 Results and Corporate Update on Feb 27 - StockTitan
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Sees Significant Decline in Short Interest - Defense World
Lisata reports positive early trial results for pancreatic cancer drug - MSN
Refractory Angina Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Gene Biotherapeutics, XyloCor Therapeutics, Centocor, Lisata Therapeutics - The Globe and Mail
Lisata Therapeutics (NASDAQ:LSTA) Trading Up 0.8% – Here’s What Happened - Defense World
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Lisata Therapeutics CEO to present at 2025 BIO CEO & Investor Conference - Proactive Investors USA
Lisata's Cancer Treatment Pipeline Takes Center Stage at Major Biotech Investor Conference - StockTitan
Lisata completes subject enrolment in multi-cancer trial of certepetide - MSN
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI - Proactive Investors UK
Lisata reports positive early trial results for pancreatic cancer drug By Investing.com - Investing.com Australia
Lisata Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA Trial Results - Proactive Investors USA
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results - Proactive Investors USA
Lisata Therapeutics and WARPNINE Announce Encouraging - GlobeNewswire
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial - Proactive Investors USA
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a - The Bakersfield Californian
Lisata's Certepetide Shows Promising Results in Pancreatic Cancer Trial, 63% Response Rate - StockTitan
Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results - MarketWatch
Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn
Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial - Proactive Investors USA
Lisata stock falls after cancer drug data (LSTA:NASDAQ) - Seeking Alpha
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 - The Bakersfield Californian
Lisata's Certepetide Shows 31% Better Survival in Pancreatic Cancer Trial Data - StockTitan
First Berlin sets Lisata stock Buy rating on innovative therapies By Investing.com - Investing.com Australia
First Berlin sets Lisata stock Buy rating on innovative therapies - MSN
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit - GlobeNewswire
Lisata Therapeutics CEO to Present at 2025 Sequire Investor Summit in Puerto Rico - StockTitan
US Penny Stocks To Watch In January 2025 - Yahoo Finance
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus - MSN
Lisata Therapeutics (NASDAQ:LSTA) Trading Up 1.4% – Still a Buy? - Defense World
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation - Simply Wall St
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors UK
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership - Proactive Investors USA
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance
Lisata Therapeutics, Inc. Announces Completion of Patient Enrollment in All Three Cohorts of the Phase 1b/2a Cendifox Trial - Marketscreener.com
Lisata Therapeutics completes patient enrollment for CENDIFOX trial - Proactive Investors Australia
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial - GlobeNewswire
Lisata Therapeutics Hits Major Milestone in Cancer Trial: Full Enrollment Complete for CENDIFOX Study - StockTitan
Lisata Therapeutics completes patient enrollment for solid tumor cancer trial - Proactive Investors USA
Neostem stock hits 52-week low at $2.41 amid market fluctuations - Investing.com Canada
Neostem stock hits 52-week low at $2.41 amid market fluctuations By Investing.com - Investing.com South Africa
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):